Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer.

Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR.

Front Biosci (Landmark Ed). 2011 Jan 1;16:368-92. Review.

PMID:
21196176
2.

Current approach to epithelial ovarian cancer based on the concept of cancer stem cells.

Djordjevic B, Stojanovic S, Conic I, Jankovic-Velickovic L, Vukomanovic P, Zivadinovic R, Vukadinovic M.

J BUON. 2012 Oct-Dec;17(4):627-36. Review.

PMID:
23335517
3.

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.

Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK.

Oncogene. 2009 Jan 15;28(2):209-18. doi: 10.1038/onc.2008.374. Epub 2008 Oct 6.

PMID:
18836486
4.

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.

5.

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

Ma L, Lai D, Liu T, Cheng W, Guo L.

Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602. doi: 10.1093/abbs/gmq067. Epub 2010 Aug 12.

PMID:
20705681
6.

Identification and characterization of cancer stem cells in ovarian yolk sac tumors.

Suzuki S, Terauchi M, Umezu T, Kajiyama H, Shibata K, Nawa A, Kikkawa F.

Cancer Sci. 2010 Oct;101(10):2179-85. doi: 10.1111/j.1349-7006.2010.01672.x. Epub 2010 Aug 27.

7.

CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.

Gao MQ, Choi YP, Kang S, Youn JH, Cho NH.

Oncogene. 2010 May 6;29(18):2672-80. doi: 10.1038/onc.2010.35. Epub 2010 Mar 1.

PMID:
20190812
8.

Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm.

Garson K, Vanderhyden BC.

Reproduction. 2015 Feb;149(2):R59-70. doi: 10.1530/REP-14-0234. Epub 2014 Oct 9. Review.

9.

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.

J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361. Epub 2010 Oct 8.

10.

CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.

Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, Sakaguchi I, Honda R, Tashiro H, Katabuchi H.

Cancer Sci. 2015 Oct;106(10):1421-8. doi: 10.1111/cas.12765. Epub 2015 Sep 21.

11.

Ovarian cancer stem cell markers: prognostic and therapeutic implications.

Burgos-Ojeda D, Rueda BR, Buckanovich RJ.

Cancer Lett. 2012 Sep 1;322(1):1-7. doi: 10.1016/j.canlet.2012.02.002. Epub 2012 Feb 11. Review.

12.

Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.

Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, Zhu YD, Diao Y, Wang AD, Lan Q.

BMC Cancer. 2008 Oct 22;8:304. doi: 10.1186/1471-2407-8-304.

13.

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY.

Oncogene. 2008 Mar 13;27(12):1749-58. Epub 2007 Sep 24.

PMID:
17891174
14.

CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.

Cui F, Wang J, Chen D, Chen YJ.

Oncol Rep. 2011 Mar;25(3):701-8. doi: 10.3892/or.2010.1115. Epub 2010 Dec 20.

PMID:
21174061
15.

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.

Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP.

PLoS One. 2010 Nov 19;5(11):e14062. doi: 10.1371/journal.pone.0014062.

16.

Apoptosis in normal and cancer stem cells.

Iannolo G, Conticello C, Memeo L, De Maria R.

Crit Rev Oncol Hematol. 2008 Apr;66(1):42-51. Epub 2007 Nov 26. Review.

PMID:
18035551
17.

CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.

Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R.

Cancer Biol Ther. 2010 Dec 1;10(11):1182-90. Epub 2010 Dec 1.

PMID:
20948317
18.

The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.

Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G.

Eur J Cardiothorac Surg. 2009 Sep;36(3):446-53. doi: 10.1016/j.ejcts.2009.03.063. Epub 2009 May 22.

PMID:
19464919
19.

Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.

Ahmed N, Abubaker K, Findlay JK.

Mol Aspects Med. 2014 Oct;39:110-25. doi: 10.1016/j.mam.2013.06.002. Epub 2013 Jun 25. Review.

PMID:
23811037
20.

Characterization of primary ovarian cancer cells in different culture systems.

Liu T, Cheng W, Lai D, Huang Y, Guo L.

Oncol Rep. 2010 May;23(5):1277-84.

PMID:
20372841

Supplemental Content

Support Center